FDA Issues Draft Guidance on Personalized Gene-Editing Treatments for Rare Diseases

Rare Daily Staff

The U.S. Food and Drug Administration has proposed a framework that could make it easier to extend personalized gene-editing treatments to people with different mutations causing the same rare disease, without requiring a separate clinical trial for every version of a treatment.

The draft guidance describes how developers could seek approval for a family of closely related treatments under a single biologics license. After approval, developers could add versions targeting additional mutations if those versions fall within agreed-upon limits and meet established safety and activity requirements.

The proposal addresses a central challenge in developing treatments for very small patient populations: A disease may result from many different mutations, while a treatment designed to correct one mutation may not work for another. FDA’s approach would allow developers to change certain targeting components while preserving a treatment’s underlying design.

The guidance remains a draft, not an implemented policy, and does not approve any treatment. It also does not eliminate the need for clinical evidence showing that a treatment family is safe and effective.

Genome editing changes DNA inside a patient’s cells. Some approaches use a guide RNA—a molecular address that directs an editing tool to a particular DNA sequence. Changing that guide could allow the same basic editing system to target a different disease-causing mutation.

The draft guidance introduces the concept of an “individualized feature space,” which defines the components that may vary across treatment versions and the limits on those changes. A new version that stays within those boundaries could be handled under the existing product license rather than requiring approval as an entirely new product.

The framework would apply to individualized genome-editing treatments for diseases caused by a single gene, where the disease-causing mutations are known. The versions covered by an application would need to produce the same intended editing outcome, such as restoring a normal DNA sequence or disabling a harmful gene variant. The framework would cover both editing performed inside the body and editing of cells outside the body before they are administered to a patient.

Developers would not be able to assume that success with one version establishes the safety and effectiveness of every possible variation. FDA says clinical data should provide the primary support for the proposed boundaries, with laboratory evidence providing additional support. The versions tested in patients should adequately represent the range the developer wants covered.

An initial approval application could include versions that have not been tested in people. But developers would need to show that those versions meet laboratory safety and activity standards and that clinical results from tested versions provide an adequate basis for predicting their performance. FDA would evaluate that justification case by case.

Each combination of guide RNA and editor would also need an assessment of unintended editing risks. Changing the molecular address can change where an editor makes unwanted alterations, even when the rest of the treatment remains the same.

For people whose mutations are too uncommon to support a conventional development program, the proposal offers a potential route to inclusion in a broader treatment family. Its practical reach will depend on how much clinical evidence FDA requires and how convincingly laboratory tests can predict the performance of versions that have not been tested in patients.